Table 1 Patient characteristics

From: Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study

All

 

N = 65

Sex

Male

35 (53.8%)

Female

30 (46.2%)

Age

Mean (SD)

52.35 (11.11)

Min–max

24–74

Performance status

0

15 (23.1%)

1

42 (64.6%)

2

7 (10.7%)

NE

1 (1.5%)

Localisation

Cardia/GEJ

18 (27.7%)

Fundus/body

16 (24.6%)

Pyloric antrum

14 (21.5%)

Linitis

17 (26.2%)

Histology

Pure SRCC

32 (49.2%)

Mixed SRCC

33 (50.8%)

Disease stage

Locally advanced

9 (13.8%)

Metastatic

56 (86.2%)

Metastatic site

Liver only

3 (5.4%)

Peritoneal carcinomatosis only

28 (50.0%)

Lung only

1 (1.8%)

Other, sites with 1 organ involved

9 (16.1%)

More than 1 organ involved

15 (26.8%)

  1. GEJ gastroesophageal junction, SRCC signet ring cell carcinoma